" Do not make the KIWI mistake of thinking the trial arms are different in ways other than drug vs no drug." ----------------- I think over all , R-IT is a well designed , well run trial. I would have preferred that they had set TG's at >200 with LDL < 100 and concentrated on recruiting prior event patients from day 1 ....but they IMHO " enriched " the study population significantly post mid 2013...so better late then never.
I like the fact that they have tight restrictions on what will be classified as unstable Angina ...ie diagnostic testing requiring hospitalization ...not just the reporting of " chest pains by a CAD patient "
I think the evidence is pretty overwhelming ...thanks Zumantu ... that we will see event reduction in the PCI ( stented ) population as well as with diabetics and CKD patients . The only question I have ...is by how much ..15%-25% RRR ?